DailyMed provides health information providers and the public with a standard, comprehensive, up-to-date, look-up and download resource of medication content and labeling as found in medication package inserts, also known as Structured Product Labeling (SPL).

The DailyMed RESTful API is a web service for accessing current SPL information. It is implemented using HTTP and can be thought of as a collection of resources, specified as URLs.

Explore the historical Whois records related to dailymed.club (Domain). Get insights into ownership history and changes over time.

The H1B Sponsorship Trends linear chart shows the number of H1B cases filed by Dailymed Pharmacy from 2020 to 2023, providing a clear view of filing trends over time. Alongside, the horizontal bar chart titled Distribution of Job Fields Receiving H1B Sponsorship breaks down which roles and industries are most commonly sponsored.

KEGG MEDICUS is an integrated database of diseases, drugs and other health-related substances. KEGG MEDICUS contains resources of KEGG DISEASE (diseases and genes), KEGG DRUG (drugs and components), KEGG PATHWAY (molecular pathways) and FDA drug labels. Users can search information on diseases and drugs against these KEGG databases and the DailyMed database in USA.

The PERM Sponsorship Trends linear chart visualizes the number of PERM cases filed by Dailymed Pharmacy from 2020 to 2023, highlighting the company’s long-term sponsorship patterns. The horizontal bar chart titled Distribution of Job Fields Receiving PERM Sponsorship further categorizes sponsored roles by job type.

The Structured Product Labeling dataset contains the most recent drug labeling information submitted to the Food and Drug Administration (FDA) and currently in use. All labels information are published by DailyMed the official provider of FDA label information.

SUMMARY

DDOD use case to request access historical label revisions of FDA-approved drugs.

WHAT IS A USE CASE?

A “Use Case” is a request that was made by the user community because there were no available datasets that met their particular needs. If this use case is similar to your needs, we ask that you add your own requirements to the specifications section.

The concept of a use case falls within the Demand-Driven Open Data (DDOD) program and gives you a formalized way to identify what data you need. It’s for anyone in industry, research, media, nonprofits or other government agencies. Each request becomes a DDOD use case, so that it can be prioritized and worked on.

Use Cases also provide a wealth of insights about existing alternative datasets and tips for interpreting and manipulating data for specific purposes.

PURPOSE

Drug manufacturers and distributions submit documentation about their products to FDA in Structured Product Labeling (SPL) that is available via openFDA. However, the approved labeling is a "living document" that is updated over time to reflect increased knowledge about the safety and effectiveness of the drug. The real-time nature of the labeling information makes it difficult to track the historical changes to a product's label and indications.

VALUE

The historical context of a product's label and indications is important in understanding how and why product labeling changes and in evaluating pharmaceutical market access.

USE CASE SPECIFICATIONS & SOLUTION

Information about this use cases is maintained in a wiki: http://hhs.ddod.us/wiki/Use_Case_25:_History_for_structured_product_labels

It serves as a knowledge base.

USE CASE DISCUSSION FORUM

All communications between Data Users, DDOD Administrators and Data Owners are logged as discussions within GitHub issues: https://github.com/demand-driven-open-data/ddod-intake/issues/25

It aims to provide complete transparency into the process and ensure the same message gets to all participants.

CASE STATUS

Closed via DailyMed, which has XML files of historical SPLs

The DDIDA database provides mechanism-based information about drugs, micromolecules and body phenotypic response (disease/symptom) relationships. The data are derived from DailyMed drug labels, DrugBank, KEGG, GenBank, OMIM, MeSH, AERS, International Classification of Diseases (ICD). It integrates drug information, micromolecular information, phenotypic response (symptom/disease), drug-adverse event information, drug-target interaction data, and micromolecule-disease relationships. The data quality is checked by experts and will be continuously updated.

The National Drug Code (NDC) Products of Unfinished Drugs dataset contains NDC product listing data submitted for all unfinished drugs. Drug products are identified and reported using a unique, three-segment number, called the National Drug Code (NDC), which serves as a universal product identifier for drugs. FDA publishes the listed NDC numbers and the information submitted as part of the listing information in the NDC Directory which is updated daily.

BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to source core information on specific bio-related topics, to collate relevant data associated with each topic and to point the user to relevant knowledge resources. We publish up to the minute news (see biotechnology news categories) and regularly update content across our information databases. BioPortfolio promotes and sells market research and management reports from 30+ publishers. In addition our unique corporate database lists 40,000+ companies and organizations. BioPortfolio aims to bring together high quality information about marketed drugs - medication and relevant clinical trials, research papers and recent news from PubMed, ClinicalTrials.gov, and DailyMed. Additionally, resources include biotech, pharma and medical job listings. When the BioPortfolio site was launched in February 1997 the company aimed to provide a global free-to-use resource with defined aims and mission statement: to meet the increasing demand of consumers, scientists, investors, commerce and government for timely, accurate and commercially useful information and intelligence on biotechnology companies, technologies and products world-wide. Driven by the success of the site we have made major investments and improvements to enhance our content and to apply the latest web technologies to improve functionality and site utility. We believe this unique depth and breadth of content is supporting individuals, organizations and policy-makers to become more aware of the role of biotechnology on the global economy. With 97,000 users visiting the site more than once per month we are confident that we are providing information our users need. We hope you the users find the site of value for both personal and professional reasons. Please enjoy this free resource and email your comments!

According to Cognitive Market Research, The Global Atropine Sulfate Injection market will expand at a compound annual growth rate (CAGR) of 2.00% from 2023 to 2030.

The demand for Atropine Sulfate Injections is rising due to the advancements in healthcare infrastructure, increasing awareness among healthcare professionals.
Demand for 1 mg/ml remains higher in the Atropine Sulfate Injection market.
The Offline Sales category held the highest Atropine Sulfate Injection market revenue share in 2023.
North American Atropine Sulfate Injection will continue to lead, whereas the Asia Pacific Atropine Sulfate Injection market will experience the most substantial growth until 2030.

Increasing Incidence of Organophosphate Poisoning to Provide Viable Market Output

The rising incidence of organophosphate poisoning will drive market growth. Atropine Sulfate is a crucial antidote in the treatment of poisoning caused by organophosphates, commonly found in pesticides and chemical warfare agents. The growing agricultural activities, coupled with the widespread use of pesticides, contribute to a higher risk of poisoning cases. As a result, the demand for Atropine Sulfate Injections as an effective therapeutic intervention in poisoning emergencies is expected to drive market growth.

In July 2023, Hikma Pharmaceuticals announced that it had begun clinical trials for its new atropine sulfate injection, which is a long-acting version of the drug.

(Source: dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c15d3cc-7888-4c82-b3f8-a5d93c5523df)

Expanding Applications in Medical Settings to Propel Market Growth

The significant driver is the expanding applications of Atropine Sulfate in various medical settings. Beyond its use as an antidote, Atropine Sulfate finds applications in ophthalmology for pupil dilation, in anesthesia to prevent bradycardia, and in the treatment of certain cardiac conditions. The versatility of Atropine Sulfate in addressing different medical needs increases its adoption across diverse healthcare scenarios. This broadened scope of applications enhances the market's growth potential as healthcare professionals recognize its efficacy in various therapeutic contexts.

In June 2023, Apotex announced that it had submitted a new drug application (NDA) to the FDA for its atropine sulfate injection.

(Source: www.apotex.com/us/about-us/press-center/2021/12/07/apotex-corp-announces-approval-and-launch-of-atropine-sulfate-ophthalmic-solution-usp-1-in-the-united-states)

Market Dynamics of the Atropine Sulfate Injection

Stringent Regulatory Framework to Restrict Market Growth

Stringent regulatory frameworks and approval processes pose another challenge for the Atropine Sulfate Injection market. The development and commercialization of pharmaceuticals, including antidotes like Atropine Sulfate, involve rigorous testing, clinical trials, and regulatory approvals. Delays or uncertainties in obtaining necessary approvals can impede the timely introduction of products to the market. Navigating complex regulatory pathways requires significant investments and expertise, impacting market entry for new players and potentially limiting the overall market growth.

Impact of COVID-19 on the Atropine Sulfate Injection Market

The COVID-19 pandemic significantly impacted the atropine sulfate injection market. The healthcare sector faced unprecedented challenges, with resources diverted toward managing the surge in COVID-19 cases. Non-urgent medical procedures and elective surgeries were postponed, affecting the demand for various medications, including Atropine Sulfate Injection. Supply chain disruptions and lockdown measures further hindered the production and distribution of pharmaceuticals. However, the pandemic underscored the importance of emergency medical interventions, potentially leading to increased awareness and utilization of Atropine Sulfate in critical situations. Introduction of The Atropine Sulfate Injection Market

Atropine Sulfate Injection contains atropine, an alkaloid derived from the Atropa belladonna plant. It competes with acetylcholine receptors and is used in medical settings for treating bradycardia, and organophosphate poisoning, and as a pre-anesthetic to inhibit salivation. Market growth is driven by advancements in healthcare infrastructure, increasing awareness among healthcare professionals, and ongoing resear...